Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom....
+See More2019-03-15 13:36:00 Friday ET
CNBC stock host Jim Cramer recommends both Caterpillar and Home Depot as the U.S. bull market is likely to continue in light of the recent Fed Chair comment
2018-09-21 09:41:00 Friday ET
Former World Bank and IMF chief advisor Anne Krueger explains why the Trump administration's current tariff tactics undermine the multilateral global tr
2025-10-08 11:34:00 Wednesday ET
Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2018-11-03 11:36:00 Saturday ET
Apple adds fresh features to its new iPad Pro and MacBook Air in addition to its prior suite of iPhone XS, iPhone XS Max, and iPhone XR back in September 20
2017-11-05 09:45:00 Sunday ET
President Trump criticizes the potential media merger between AT&T and Time Warner, the latter of which owns the anti-Trump media network CNN. President
2018-03-29 14:28:00 Thursday ET
Share prices tumble for technology stocks due to Trump's criticism of Amazon's tax avoidance, Facebook user data breach of trust, and Tesla autopilo